662
Participants
Start Date
February 16, 2022
Primary Completion Date
February 28, 2027
Study Completion Date
February 28, 2027
Tranexamic Acid
"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
RECRUITING
Tom Baker Cancer Centre, Calgary
RECRUITING
Cross Cancer Institute, Edmonton
NOT_YET_RECRUITING
Memorial University, St. John's
NOT_YET_RECRUITING
Dalhousie University, Halifax
NOT_YET_RECRUITING
Hopital Maisonneuve-Rosemont, Montreal
RECRUITING
Saskatchewan Cancer Agency, Saskatoon
RECRUITING
Eastern Regional Health Authority, St. John's
RECRUITING
Hamilton Health Sciences - Juravinski Hospital and Cancer Centre, Hamilton
RECRUITING
London Health Sciences Centre, London
RECRUITING
The Ottawa Hospital, Ottawa
WITHDRAWN
Princess Margaret Cancer Centre, Toronto
Lead Sponsor
Alberta Cancer Foundation
OTHER
Ottawa Hospital Research Institute
OTHER